Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation | Zendy

Emil Loldrup Fosbøl | Zendy; Naja Emborg Vinding | Zendy; Morten Lamberts | Zendy; Laila Stærk | Zendy; Anna Gundlund | Zendy; Kasper Gadsbøll | Zendy; Lars Køber | Zendy; Gunnar Gislason | Zendy; Jonas Bjerring Olesen | Zendy

AI Assistant Blog Pricing

Open Access

Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation

Author(s) -

Emil Loldrup Fosbøl,

Naja Emborg Vinding,

Morten Lamberts,

Laila Stærk,

Anna Gundlund,

Kasper Gadsbøll,

Lars Køber,

Gunnar Gislason,

Jonas Bjerring Olesen

Publication year - 2017

Publication title -

ep europace

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.119

H-Index - 102

eISSN - 1532-2092

pISSN - 1099-5129

DOI - 10.1093/europace/eux193

Subject(s) - vitamin k antagonist , antagonist , atrial fibrillation , medicine , vitamin , vitamin k , cardiology , pharmacology , warfarin , receptor

After non-vitamin K antagonist (VKA) oral anticoagulation agents (NOAC) have been approved for thrombo-embolic prophylaxis in non-valvular atrial fibrillation (NVAF), utilization of oral anticoagulants (OAC) in NVAF has changed. Contemporary shifting from a VKA to a NOAC (dabigatran, rivaroxaban, or apixaban) has not been quantified, and could help assess whether these drugs are used according to recommendations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog